Federation Francophone De Cancerologie Digestive

This phase II trial tests whether a genetic signature can personalize chemotherapy for people with borderline resectable pancreatic cancer. About 110 participants will receive either a standard chemo regimen or one chosen based on their tumor's genetic profile. The goal is to see…

This phase 2 trial tests whether a new drug called fruquintinib, combined with standard chemotherapy, can control advanced colorectal cancer better than the current standard treatment (bevacizumab plus chemotherapy). About 74 adults whose cancer has worsened after first-line ther…